Tag Archives: Monoclonal antibodies

21May/26

Why Ebola Borders Must Stay Open

May 21, 2026HealthcareAnsuvimab, Biological agents, Bundibugyo, Bundibugyo ebolavirus, Congo, Ebola, Ebolavirus, Ituri, Kampala, Kinshasa, Monoclonal antibodies, Recombinant vesicular stomatitis virus vaccines, RVSV-ZEBOV vaccine, Tropical diseases, Uganda, West African Ebola virus epidemic, Zaire ebolavirusadmin

The 2026 Bundibugyo Ebolavirus Epidemic and Research Landscape

Thur, May 21 2026 /Mpelembe Media/ — The 2026 Global Health Emergency In May 2026, the World Health Organization (WHO) declared the outbreak of the Orthoebolavirus bundibugyoense (Bundibugyo virus) in the Democratic Republic of the Congo (DRC) and Uganda a Public Health Emergency of International Concern (PHEIC). The epidemic, which originated in the Ituri Province of the DRC and expanded into Kampala, Uganda, has exposed significant vulnerabilities in international disease surveillance and containment. The rapid spread of the virus has been exacerbated by a combination of cross-border dynamics, high-traffic mining operations, and regional humanitarian crises. Continue reading →

01Sep/23

New Alzheimer’s drugs don’t deserve the hype – here’s why

September 1, 2023MedicineAducanumab, Alzheimer's disease, Alzheimer's disease in African Americans, Amyloid beta, Amyloidosis, Cognitive disorders, Creative Commons, crenezumab, Dementia, Donanemab, Lecanemab, Monoclonal antibodies, Sebastian Walsh, SHUTTERSTOCK, United Kingdom, United Statesadmin

Sebastian Walsh, University of Cambridge

A prominent childhood memory is of my grandparents living with and then dying from dementia. As is universal with dementia, there was a double blow: watching my grandparents lose their identity and seeing the suffering of those closest to them.

Continue reading →

18Jul/23

ALZHEIMER’S ASSOCIATION STATEMENT ON DONANEMAB PHASE 3 DATA REPORTED AT AAIC 2023

July 18, 2023ReasearchAAIC, Alzheimer's Association, Alzheimer's disease, Amsterdam, Clinical trial, Donanemab, Eli Lilly, Eli Lilly and Company, Monoclonal antibodies, Netherlandsadmin

The data reported today by Eli Lilly from the TRAILBLAZER-ALZ 2 clinical trial of donanemab in early symptomatic Alzheimer’s disease demonstrate an important advancement in Alzheimer’s research and treatment. The full Phase 3 data was reported at the Alzheimer’s Association International Conference® (AAIC®) 2023, in Amsterdam, Netherlands, and online. The data were simultaneously published in the Journal of the American Medical Association. Continue reading